For the publisher Elsevier, antivax papers are apparently only a problem when they are too heavily manipulated. It took their journal 12 years to retract the notorious paper by Andrew Wakefield, because of data irregularities (details here and here). But the damage was done, an worldwide antivax movement was born, which keeps spreading bizarre and irrational paranoia that vaccines would cause autism in children (most recently supported by the disastrous US president Donald Trump, in tweets and in actual governmental policy). Vaccination rates dropped worldwide, and consequently deadly diseases considered long eradicated are making a comeback. But scholarly publishers and their journals bear here a heavy responsibility, by repeatedly publishing antivax papers and providing the anti-vax movement with the scientific legitimacy.
This was exactly what Elsevier did just now, again. Their Journal of Inorganic Chemistry published a paper by notorious antivax researchers Christopher Shaw, ophthalmology professor in the University of British Columbia, and his postdoc Lucija Tomljenovic. Both scientists enjoy full support of their Canadian university, despite that, together with another antivaxer, Yehuda Schoenfeld, they once had to retract a paper on the alleged neurotoxicity of aluminium adjuvant in vaccines, from the Elsevier journal Vaccine. The authors then simply republished the retracted masterpiece again in another journal, Immunologic Research, published by Springer.
The newly published Shaw paper in Journal of Inorganic Chemistry is again about alleged neurotoxicity of aluminium (or as authors prefer to call it, “aluminum”) , with a bold claim that it would cause autism in mice, as detected by some biomarkers authors saw as appropriate:
Continue reading “The rise and fall of an antivax paper, by Smut Clyde”
Recent news brought us yet another retraction of the Spanish zombie scientist Susana Gonzalez, formerly famous for her impactful ERC-funded research into stem cells and ageing. It is her fifth retraction (others here), and meanwhile Gonzalez is not even a zombie scientist anymore. She has no research group in her new Madrid institute, noone in Spain wants to work in the same building with her, in fact though she is still formally employed with the Spanish Consejo Superior de Investigaciones Científicas (CSIC), it seems she stopped coming to work long ago, being on an endless sick leave. Even the European Research Council (ERC), usually most accommodating with research misconduct of their elite grant recipients, didn’t know what to do with Gonzalez suspended €2Mn grant and eventually terminated it.
The recent Gonzalez retraction at the Molecular and Cellular Biology (MCB) is interesting in two aspects. First, Retraction Watch previously chastised the journal in a headline for allegedly refusing to investigate evidence of data manipulations in papers older than 6 years (read here). No reference is made to that “smear” accusation in the current Retraction Watch article on Gonzalez retraction. But the second aspect is really much more intriguing. The retracted MCB paper, from Gonzalez period as postdoc at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, was coauthored by the US researcher Carol Prives, professor at the Columbia University in New York, and specialist for the cell cycle control protein p53: Continue reading “Carol Prives, innocent victim of Susana Gonzalez’ data manipulations?”
It is now quasi official: do not mess with Frontiers. My earlier reporting made it a credible possibility that this Swiss publisher was behind the January 2017 shut-down and removal of Jeffrey Beall’s list of “potential, possible, or probable predatory scholarly open-access publishers”, and it was now indeed verified by an article in Chronicle of Higher Education. The librarian Beall used to be constantly under attack from Open Access (OA) publishers who were unhappy about his personal opinions and his private decisions to place them on his blog list. With those, his University of Colorado in Denver supported Beall. But the trouble started when he placed in October 2015 the Swiss publisher Frontiers onto his list, thus effectively declaring this Holtzbrinck-owned outlet a predatory publisher, after hearing of scientists’ complaints and reading my reports. To be fair, Frontiers are still defended by a much bigger number of scientists who see the advantage of having a reliable business partner who will publish certain manuscripts which hardly any respectable journal might consider. Especially certain kinds of psychologists figured out that with the life-science-oriented Frontiers they can easily get merited as proper neuroscientists, or even biomedical polymaths (e.g., here). Regardless of the bunk they place there for $2500 a pop.
Frontiers first tried it nicely with Beall, when the Chief Executive Officer Frederick Fenter and journal manager Mirjam Curno (who is also trustee at Committee for Publication Ethics, COPE, read here) visited the librarian before Christmas 2016 in Denver (see my report here). Since Beall still did not remove Frontiers from his list, Fenter rallied its loyal journal editors and started together with them in August 2016 a campaign against Beall, demanding that his university punishes the librarian or at least forces him to remove Frontiers from his private list (read here). That information on my site served as (utterly uncredited) template for the aforementioned Chronicle of Higher Education article (as its author Paul Basken admitted to me, but his editor Brock Read denied). Basken then contacted Beall, who then also revealed to him that in January 2016 the University of Colorado Denver caved in to Frontiers demands and opened a misconduct case against its librarian. At this point, Beall decided to delete his list and save his job. An academic disagreement was resolved in a honed and cherished academic tradition: with a call to the employer and a threat of sacking.
Continue reading “Frontiers: vanquishers of Beall, publishers of bunk”
The European Commission now took 40 days to deny my second Freedom of Information (FOI) Inquiry about the TETRA phase 2 clinical trial with cadaveric trachea transplant they are currently financing with €7 Million. This is EU’s second attempt to become world-leading manufacturer of industrial trachea transplants, after the €5mn Biotrachea led by the scandal surgeon Paolo Macchiarini was terminated mid-term. No, not because EU had any concerns for the patients, quite the opposite: he was given a clean ethics vote to go ahead. Biotrachea was terminated by the EU because the plastic tracheas Macchiarini wanted to use lacked novelty, as the documents I obtained revealed.
The TETRA trial, led by Macchiarini’s past collaborator, the UCL laryngologist Martin Birchall, was already on the brink of being terminated in the wake of the Macchiarini scandal, as EU previously indicated to me. Now, exactly the opposite happens. The trial is being prepared at full speed despite the fact that its predecessor phase 1 trial INSPIRE was suspended (because of my reporting), never recruited any of its four patients and it most likely never will. That trial is also led by Birchall (details here), it is likely that its Innovate UK funding has ran out meanwhile. EU however seems to signal that they will go ahead with phase 2 trial even if phase 1 never happens. After all, there are those 10 patients who received a cadaveric trachea transplant (here and below) and were operated under hospital exemptions between 2008 and 2012 by Macchiarini and Birchall. At least half of these 10 are dead, the lucky survivors either had their graft removed or live with permanently installed stents to prevent their rotting airways from collapsing (INSPIRE’s and TETRA’s clinical promise is actually that the patients will never need a stent). But this disaster seems exactly the reason for EU to try it again, and on a much, much bigger scale: 48 patients are scheduled to receive cadaveric tracheas. Probably because it will create employment.
The EU spokesperson ceased long ago answering my emails, after I declined to be instructed over the phone (strictly off-the-record) why EU’s approach to trachea transplanting is right; this is why I had to resort to FOI. The official time limit to answer my FOI inquiry from July 1st 2017 was 15 days, but the EU first pretended not to have received my postal address, then said they need more time, then said they need extra time to assemble the documents for me, and finally, the Director-General of the European Commission, Robert-Jan Smits, wrote to me on September 11th. He basically told me again to get lost and that he will never release any information (read here his past rejection of my FOI inquiry). His reasons, as before: the trachea transplant trial is a business enterprise and revealing any of its progress might endanger the financial interests of its stakeholders, and then there are privacy concerns. Exactly, Smits decided that the public must under no circumstances find out whom exactly the EU is giving this public’s money for research on humans. I am not making it up, read Smits’ letter yourself here. Continue reading “EU commemorates dead patients of Macchiarini & Birchall with a phase 2 trachea transplant trial TETRA”
Regarding the Olivier Voinnet scandal and a recent data integrity case in Germany (marginally featuring a current group leader of the John Innes Centre in Norwich, UK), I had an email exchange with the director of this British plant science research centre, Dale Sanders. It started with Sanders demanding of me to cease-and desist from ever associating the misconduct-tainted cheater professor Voinnet with his John Innes Centre (despite that connection being very well-documented), and ended with Sanders calling me an “internet troll” and decreeing that my Voinnet reporting is not worth ever being read because it has not been peer reviewed.
The whole case revolves around the former star of plant sciences and current ETH professor Voinnet, though it is actually not at all about him or his own data manipulations. In July 2017, I brought an article, where concerns about the data integrity in publications of a very senior and influential German yeast biologist, Roland Lill, were raised on PubPeer. A past member of Lill’s lab, his PhD student Heike Lange, is now tenured researcher at the same CNRS institute in Strasbourg where Voinnet did most of his data manipulations. Lange has a number of papers which contain what clearly looks like duplicated western blot bands, she and LIll went to PubPeer to declare that the bands were never duplicated (details in my article). Yet Lange and Lill never substantiated their claims or showed any original gel scans for their common papers, which lets one wonder if those actually exist.
It turned out somewhat differently with another former PhD student of Lill, Janneke Balk, who is now the above mentioned group leader at Sanders’ John Innes Centre. Two common papers of Balk and Lill were flagged on PubPeer: Balk et al EMBO J 2004 and Balk et al, Mol Cell Biol. 2005. She has not managed to address the concerns about the former yet (more about it later), but she did reply on PubPeer to the evidence of gel band duplication by admitting the copy-paste, posting the original gels and explaining at length exactly which band was duplicated and why:
Continue reading “John Innes Centre director Dale Sanders rebuffs a non-peer reviewed internet troll”
The Kafkaesque farce of court injunction trials from German trachea transplanters against me continues. The Landesgericht court in Berlin issued a second injunction against me, as requested by the angel of innocence Philipp Jungebluth, the former right hand man and acolyte of Paolo Macchiarini. The target of the injunction is this article, concerning an unpublished Macchiarini paper Haag et al. As it practice in German law, this legally binding verdict, the breach of which is punishable by a fine of up to €250,000, was passed without allowing me to present my evidence. In fact, Jungebluth also was not asked to present any evidence, his word that I wronged him sufficed. The legal idea behind such injunctions “the element of surprise”, that is, to present the other party with a binding court verdict, a huge bill for it, followed by a huge fine for any alleged breach of the injunction, the pretext for which is always easy to conjure, all of which should discourage any attempts to fight back. You are expected to lose your court case without even knowing there was one going on. Germans think this is a great and just way to keep internet and other media at bay.
So this is obviously a financially heavily mismatched war of Macchiarini and his partners against me, with all the media who used to celebrate their (now known as lethal) human experiments suddenly very silent. I am however grateful for the past and current support of my readers, and ask you to keep donating. Because nobody in Germany cares about these dead and mutilated patients, who were all foreigners experimented upon abroad anyway. Continue reading “Berlin court grants Jungebluth new injunction against my reporting”
More suspected data manipulations in the papers by the French elite biologists. It was funny enough when the director and several lead figures at the Strasbourg CNRS institute for plant sciences IBMP, former home of the master data manipulator Olivier Voinnet, and even the institute’s evaluators, were found to sport quite a lot of shifty-looking data in their papers. This time, the irony is just too much. Catherine Jessus, developmental biologist specialising on cell cycle research on oocytes and director of CNRS l’Institut des sciences biologiques (INSB) was in charge of two misconduct cases, and now the data integrity of her own papers is called in question. One investigation led by Jessus was about, whom else, Voinnet and his IBMP sidekick Patrice Dunoyer. In summer 2015, Voinnet was barred from CNRS for 2 years (which sounds worse than it is, because his professorship at ETH Zürich in Switzerland remained untouched, read here), and Dunoyer was suspended for one entire month. Jessus’ secret investigation ended with no documents whatsoever but a terse press release made available to outsiders. Both Voinnet and Dunoyer are by now back to publishing papers in prestigious journals.
Jessus was also in charge of dealing with the misconduct evidence against Voinnet’s former postdoc Charles-Henri Lecellier, whom the mighty plant scientist (according to my sources) banned from his Strasbourg lab because he did not trust his research results. It seems Lecellier started to fudge data already during his PhD at CNRS Hôpital Saint-Louis in Paris (PubPeer record here). Imagine how bad it must get that Voinnet expels you for data manipulation! The tenured CNRS researcher was hence moved out of Voinnet’s sight, to work as group leader at the Institut de Génétique Moléculaire de Montpellier, where he continued his own line of data rigging, helped by his trusted friend from IBMP, Guillaume Vetter (see my earlier reporting for a German magazine here and here). Apparently, with full protection from CNRS: in 2013 Jessus actively opposed on behalf of CNRS the impending retraction of a Lecellier co-authored paper, despite earlier misconduct findings against his partner Vetter at the University of Luxembourg (evidence here, especially this letter, example of data manipulations here).
Continue reading “Voinnet’s CNRS investigator Catherine Jessus with own data integrity issues”